Related Experiment Video
Updated: Jun 2, 2025
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden
Qianying Zuo1, Jin Young Yoo1, Erik R Nelson2,3,4
1Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Abstract:
Patients with metastatic breast cancer face reduced quality of life and increased mortality rates, necessitating more effective anti-cancer strategies. Building on previous research that identified metastatic-niche-specific metabolic vulnerabilities, we investigated how a ketogenic diet enhances estrogen receptor (ER)-positive liver metastatic breast cancer's response to Fulvestrant (Fulv) treatment. Using in vitro cell lines and in vivo xenograft metastasis mouse models, we examined the molecular mechanisms of combining ER targeting with a ketogenic diet. We found that Fulv treatment downregulates the ketogenesis pathway enzyme OXCT1, leading to β-hydroxybutyrate accumulation and decreased tumor cell viability. We also explored interactions between glucose, palmitic acid, and β-hydroxybutyric acid. These findings establish the molecular basis and clinical potential of a ketogenic diet to enhance Fulv efficacy in patients with ER+ liver metastatic breast cancer, potentially improving survival outcomes and quality of life in this population.
Insights
A ketogenic diet may improve treatment for estrogen receptor-positive liver metastatic breast cancer. Combining this diet with Fulvestrant (Fulv) therapy shows potential to enhance anti-cancer effects and improve patient outcomes.
Area of Science:
- Oncology
- Metabolic Research
- Cancer Therapeutics
Background:
- Metastatic breast cancer, particularly ER-positive liver metastases, presents significant challenges in patient quality of life and survival.
- Targeting metabolic vulnerabilities within the tumor microenvironment is a promising strategy for enhancing anti-cancer therapies.
- Estrogen receptor (ER) targeted therapies like Fulvestrant (Fulv) are standard, but resistance and efficacy can be improved.
Purpose of the Study:
- To investigate the synergistic effects of a ketogenic diet combined with Fulvestrant (Fulv) treatment in ER-positive liver metastatic breast cancer.
- To elucidate the molecular mechanisms underlying the enhanced efficacy of Fulv when combined with a ketogenic diet.
- To explore the role of metabolic pathways, specifically ketogenesis, in mediating treatment response.
Main Methods:
- Utilized in vitro cell line models of ER-positive liver metastatic breast cancer.
- Employed in vivo xenograft metastasis mouse models to assess treatment efficacy and mechanisms.
- Analyzed molecular changes, including enzyme expression (OXCT1) and metabolite levels (β-hydroxybutyrate), in response to Fulv and ketogenic diet.
Main Results:
- Fulvestrant (Fulv) treatment was found to downregulate the ketogenesis enzyme OXCT1.
- This downregulation led to an accumulation of β-hydroxybutyrate, a ketone body, which decreased tumor cell viability.
- Interactions between glucose, palmitic acid, and β-hydroxybutyric acid were explored, revealing complex metabolic interplay.
Conclusions:
- A ketogenic diet can enhance the efficacy of Fulvestrant (Fulv) in ER-positive liver metastatic breast cancer.
- The combination therapy shows potential by modulating metabolic pathways, specifically the ketogenesis pathway via OXCT1.
- This approach offers a promising strategy to improve survival outcomes and quality of life for patients with this specific breast cancer subtype.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:15Drugs that Stabilize Microtubules